As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D
Medicilon's drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. Our chemistry team can deliver complex activities such as custom synthesis of compounds, compound library construction, SAR analysis and screening, compound structure determination and bioactivity optimization.
Medicilon's biology team offers a complete suite of biology services from protein expression, protein purification, protein and protein-compound co-crystallization, enzymology, cytological bioactivity screening, protein-protein and protein-small molecule affinity testing, virtual screening, and computer-assisted drug design.
Medicilon is a Preclinical Research Outsourcing (CRO) company. With more than 20 years of experience on preclinical research services, we are dedicated to provide our clients with customized preclinical services program in drug metabolism, pharmacokinetics, efficacy studies, and toxicology. We provide our clients a high-quality data and rapid turnaround time to support their drug development, preclinical studies and clinical research and to help them to select the most valuable drug candidates for clinical development.
Medicilon's preclinical research services consist of three major parts: pharmacokinetics, disease models and drug safety evaluation. Our preclinical research services cover design, in vivo studies, sample analysis, data analysis, IACUC review, and the preparation of regulatory application materials.
Based on the technical basis of flow cytometry, the Medicilon flow sorting platform is widely used in our scientific research and specific work in immunology, cell biology, oncology, hematology, drug development, and environmental testing.
The Medicilon flow cytometry team has extensive experience in experimental operation, flow sorting method development and data analysis. The platform is equipped with a SONY flow cell sorter, which is capable of sorting of up to 6 colors at the same time, and statisfy the special scientific research and sorting needs of clients.
Cardiovascular and cerebrovascular diseases generally refer to ischemic or hemorrhagic diseases of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and hypertension.Model evaluation is a critical step in testing results. Medicilon strictly follows the STAIR preclinical drug development strategy for stroke and has significant experience in MCAO model establishment and a mature MCAO model system evaluation system.
STAT3, a member of the STAT family, is a latent transcription factor that is activated in response to various cytokines, growth factors, and oncogene signals. STAT3 is constitutively activated in various human cancers, and its activation is frequently associated with poor prognosis. As a transcription factor, STAT3 regulates a set of genes implicated in cancer cell survival, proliferation, angiogenesis, invasion, metastasis, drug resistance, and immune evasion. Medicilon provides STAT3 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.
RAS is one of the most frequently mutated oncogenes in human cancer. KRAS is the isoform most frequently mutated, which constitutes about 85% of RAS mutations. As the most frequently mutated RAS isoform, KRAS is intensively studied in the past years.
In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides KRAS-targeted drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.
marketing@medicilon.com
ABOUT
